• Share
  • Magazine doorsturen
  • Contact
  • Zoeken in edities
  • Volledig scherm

  • Team Interactieve Media 2016
    Team Interactieve Media 2016
  • Jaarbeeld 2016 afdeling Genetica
    Jaarbeeld 2016 afdeling Genetica
  • Speerpunt Cancer Center
    Speerpunt Cancer Center
  • Jaarbeeld Urologie 2015
    Jaarbeeld Urologie 2015
  • Jaarbeeld Cardiologie 2015
    Jaarbeeld Cardiologie 2015
  • Annual Report Heart & Lungs 2015
    Annual Report Heart & Lungs 2015
  • Jaarbeeld Hart & Longen 2015
    Jaarbeeld Hart & Longen 2015
  • Duurzaamheidsverslag 2015, UMC Utrecht
    Duurzaamheidsverslag 2015, UMC Utrecht
  • Strategie facilitair bedrijf
    Strategie facilitair bedrijf
  • Jaarbeeld Cardiologie 2014
    Jaarbeeld Cardiologie 2014
  • Patient Centraal
    Patient Centraal
  • Jaarbeeld divisie Vrouw & Baby 13/14
    Jaarbeeld divisie Vrouw & Baby 13/14
  • Heart & Lungs in business, annual report 2014
    Heart & Lungs in business, annual report 2014
  • Hart & Longen in bedrijf, jaarbeeld 2014
    Hart & Longen in bedrijf, jaarbeeld 2014
  • Resultaten in balans
    Resultaten in balans
  • Jaarbeeld Cardiologie 2013
    Jaarbeeld Cardiologie 2013
  • Annual report Cardiology 2013
    Annual report Cardiology 2013
  • Jaarbeeld Cardiologie 2013 A4
    Jaarbeeld Cardiologie 2013 A4
  • Jaarbeeld Hart & Longen 2013
    Jaarbeeld Hart & Longen 2013
  • Annual report Heart & Lungs 2013
    Annual report Heart & Lungs 2013
  • MVO Magazine
    MVO Magazine

Prof.dr. Pieter Doevendans,

Medical Manager and Chairman

 

Prof.dr. Marc Vos,

Research and Education Manager

 

Robert van Barneveld MHA,

Healthcare Manager

 

Karin Krol-Simons RA,

Business Manager

MANAGEMENT TEAM

Home

The year 2013 at the Division of Heart & Lungs was marked mainly by investments in the future. Investments were made in the fields of patient care, research and education, as evidenced by the results outlined in this year end report. Investing in cutting-edge research allows us to build further on the progress we have already made by generating significant research results and eventually creating optimal treatments for our patients. Investment also means initiating and strengthening national and international collaborations because we can achieve more when we join forces. We invest in the care we give our patients by offering new treatments. We were granted JCI accreditation in 2013, which means that our organization meets international quality standards in the field of care, research and education. This was also an investment in the future, because quality is never a finished product - we can always improve.

 

At the Division of Heart & Lungs, we fulfill our ambitions together. This year end report shows that we have yet again set the bar a little higher this year. I hope that we can continue working together equally as motivated again next year.

 

Prof. Pieter Doevendans

Medical Manager and Chairman

Division of Heart & Lungs

medisch manager en voorzitter

Divisie Hart

FOREWORD

  • MENU
  • 2 - 11
  • Share
Overzicht edities

Team Interactieve Media 2016

Jaarbeeld 2016 afdeling Genetica

Speerpunt Cancer Center

Jaarbeeld Urologie 2015

Jaarbeeld Cardiologie 2015

Annual Report Heart & Lungs 2015

Jaarbeeld Hart & Longen 2015

Duurzaamheidsverslag 2015, UMC Utrecht

Strategie facilitair bedrijf

Jaarbeeld Cardiologie 2014

Patient Centraal

Jaarbeeld divisie Vrouw & Baby 13/14

Heart & Lungs in business, annual report 2014

Hart & Longen in bedrijf, jaarbeeld 2014

Resultaten in balans

Jaarbeeld Cardiologie 2013

Annual report Cardiology 2013

Jaarbeeld Cardiologie 2013 A4

Jaarbeeld Hart & Longen 2013

Annual report Heart & Lungs 2013

MVO Magazine